Optimizing SARS-CoV-2 Immunoassays for Specificity in Dengue-Co-Endemic Areas.

Autor:	Adnan N; Microbiology, Jahangirnagar University, Dhaka, BGD., Haq MA; Bio-Statistics, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b), Dhaka, BGD., Tisha TA; Microbiology, Jahangirnagar University, Dhaka, BGD., Khandker SS; Biochemistry and Molecular Biology, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD., Jamiruddin MR; Pharmacy, Bangladesh Rural Advancement Committee (BRAC) University, Dhaka, BGD., Sajal SSA; Biochemistry and Molecular Biology, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD., Akter S; Microbiology, Jahangirnagar University, Dhaka, BGD., Ahmed MF; Microbiology, Jahangirnagar University, Dhaka, BGD., Raqib R; Immunology, Nutrition, and Toxicology Laboratory, Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b), Dhaka, BGD., Khondoker MU; Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Dhaka, BGD., Azmuda N; Microbiology, Jahangirnagar University, Dhaka, BGD., Haque M; Department of Research, School of Dentistry, Karnavati Scientific Research Center (KSRC) Karnavati University, Gandhinagar, IND.; Pharmacology and Therapeutics, National Defence University of Malaysia, Kuala Lumpur, MYS.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Oct 25; Vol. 15 (10), pp. e47683. Date of Electronic Publication: 2023 Oct 25 (Print Publication: 2023).
DOI:	10.7759/cureus.47683
Abstrakt:	Introduction The overlap in clinical presentation between COVID-19 and dengue poses challenges for diagnosis in co-endemic regions. Furthermore, there have been reports of antibody cross-reactivity between SARS-CoV-2 and dengue. Our research aims to evaluate SARS-CoV-2 antigens for serological testing while reducing the possibility of cross-reactivity with anti-dengue antibodies. Method Two hundred and ten serum samples were collected from 179 patients and divided into four panels. Panels 1 and 2 consisted of COVID-19-negative healthy donors (n=81) and pre-pandemic dengue patients (n=50), respectively. Alternatively, Panel 3 (n=19) was composed of reverse transcription-quantitative polymerase chain reaction (RT-qPCR)-positive samples collected within two weeks of COVID-19 symptom onset, while Panel 4 (n=60) was composed of positive samples collected after two weeks of symptom onset. Previously developed and characterized in-house SARS-CoV-2 spike-1 (S1), receptor binding domain (RBD), and nucleocapsid (N) immunoglobin G (IgG)-enzyme-linked immunosorbent assay (ELISA) assays were used for the study. Results Six dengue-positive sera cross-reacted with the RBD of SARS-CoV-2. However, only one dengue-positive sera cross-reacted with the S1 and N proteins of SARS-CoV-2. Co-immobilization of S1 and RBD in different ratios revealed an 80:20 (S1:RBD) ratio as optimal for achieving an overall 96.2% sensitivity with the least cross-reaction to anti-dengue antibodies. Conclusion Our findings indicated that SARS-CoV-2 RBD-based immunoassays present more cross-reactivity with anti-dengue antibodies than S1 and N proteins. Furthermore, co-immobilization of S1 and RBD reduces the cross-reactivity with anti-dengue antibodies compared to RBD, thereby increasing the immunoassay specificity without affecting overall sensitivity for the dengue-endemic areas. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Adnan et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu